Competition and Markets Authority (CMA) opens investigation into suspected anti-competitive practices in the supply of lithium-based drugs used to treat bipolar disorder

CMA will investigate whether Essential Pharma has abused dominant position by proposing to withdraw supply of Priadel to UK patients. The withdrawal of Priadel would mean thousands of patients need to switch to alternative, more expensive, lithium treatments, such as Camcolit.

Source:

Competion and Markets Authority